Pharmaceuticals Ltd.


Preventerm is derived from a naturally occurring amino acid derivative and thiol reducing agent This drug is exceptionally easy to manufacture, as it draws from a widely available molecule Preventerm is ready to begin Phase II testing by our research team

Inducterm is created from ubiquitous collagenase, an enzyme that governs the breakdown of collagen in various human and animal systems Collagenase is already FDA approved for unrelated indications and in use by Biospecifics Technology Corp. (US) for tissue healing therapies Inducterm is ready to begin clinical trials Phase II.

With this device dual use Local immunological injection: For induction if labor – 1 Injection 

For the prevention and treatment of preterm labor injections with a two weeks interval.


Various scientific case reports on the use of the Preventerm source molecule report no adverse side effects to the mother or infant

Initial tests of Preventerm have shown a 90% efficacy rate in preventing preterm labor – overwhelmingly more effective than any of the currently available treatment modalities

Preventerm stands to decrease the overall expense of preterm infant health care and will reduce infant mortality as well as post-natal complications considerably

We intend to generate revenue through joint and/or strategic collaborations with large pharmaceutical and biotechnology companies in order to further develop our products, jointly facilitate regulatory approval, and subsequently to bring our products to the global markets

A unique investment opportunity: Patented and patent-pending breakthrough drugs Direct solution to a pressing market need Vast expertise in the OB/Gyn industry Several discrete multi-billion dollar markets Strategic value to large pharmaceutical companies